NCT02989844View on ClinicalTrials.gov

Relapse Prophylaxis With N-803 for AML and MDS Pts Following Allo HSCT

PHASE2CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

April 12, 2017

Primary Completion Date

March 19, 2022

Study Completion Date

August 31, 2022

Conditions
Acute Myelogenous Leukemia (AML)Myelodysplastic Syndrome (MDS)
Interventions
DRUG

N-803

N-803 at 6 mcg/kg SQ Day 1 of a 4 week (28 day) cycle with ± 1 week window Continue N-803 every 4 weeks for 10 doses or until relapse, unacceptable toxicity, or patient refusal, whichever comes earlier.

Trial Locations (1)

55455

Masonic Cancer Center at University of Minnesota, Minneapolis

All Listed Sponsors
lead

Masonic Cancer Center, University of Minnesota

OTHER

NCT02989844 - Relapse Prophylaxis With N-803 for AML and MDS Pts Following Allo HSCT | Biotech Hunter | Biotech Hunter